447 related articles for article (PubMed ID: 34895860)
1. A Systematic Review and Network Meta-Analysis of Pharmacological Treatment of Heart Failure With Reduced Ejection Fraction.
Tromp J; Ouwerkerk W; van Veldhuisen DJ; Hillege HL; Richards AM; van der Meer P; Anand IS; Lam CSP; Voors AA
JACC Heart Fail; 2022 Feb; 10(2):73-84. PubMed ID: 34895860
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological Treatments in Heart Failure With Mildly Reduced and Preserved Ejection Fraction: Systematic Review and Network Meta-Analysis.
Zafeiropoulos S; Farmakis IT; Milioglou I; Doundoulakis I; Gorodeski EZ; Konstantinides SV; Cooper L; Zanos S; Stavrakis S; Giamouzis G; Butler J; Giannakoulas G
JACC Heart Fail; 2024 Apr; 12(4):616-627. PubMed ID: 37656079
[TBL] [Abstract][Full Text] [Related]
3. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.
Martin N; Manoharan K; Davies C; Lumbers RT
Cochrane Database Syst Rev; 2021 May; 5(5):CD012721. PubMed ID: 34022072
[TBL] [Abstract][Full Text] [Related]
4. Network meta-analysis of medical therapy efficacy in more than 90,000 patients with heart failure and reduced ejection fraction.
De Marzo V; Savarese G; Tricarico L; Hassan S; Iacoviello M; Porto I; Ameri P
J Intern Med; 2022 Aug; 292(2):333-349. PubMed ID: 35332595
[TBL] [Abstract][Full Text] [Related]
5. The impact of heart failure therapy in patients with mildly reduced ejection fraction: a network meta-analysis.
Leite M; Sampaio F; Saraiva FA; Diaz SO; Barros AS; Fontes-Carvalho R
ESC Heart Fail; 2023 Jun; 10(3):1822-1834. PubMed ID: 36896801
[TBL] [Abstract][Full Text] [Related]
6. Comparative cardiovascular outcomes of novel drugs as an addition to conventional triple therapy for heart failure with reduced ejection fraction (HFrEF): a network meta-analysis of randomised controlled trials.
Suebsaicharoen T; Chunekamrai P; Yingchoncharoen T; Tansawet A; Issarawattana T; Numthavaj P; Thakkinstian A
Open Heart; 2023 Nov; 10(2):. PubMed ID: 37940331
[TBL] [Abstract][Full Text] [Related]
7. Pharmacotherapies in Heart Failure With Preserved Ejection Fraction: A Systematic Review and Network Meta-Analysis.
Sreenivasan J; Malik A; Khan MS; Lloji A; Hooda U; Aronow WS; Lanier GM; Pan S; Greene SJ; Murad MH; Michos ED; Cooper HA; Gass A; Gupta R; Desai NR; Mentz RJ; Frishman WH; Panza JA
Cardiol Rev; 2024 Mar-Apr 01; 32(2):114-123. PubMed ID: 36576372
[TBL] [Abstract][Full Text] [Related]
8. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.
Martin N; Manoharan K; Thomas J; Davies C; Lumbers RT
Cochrane Database Syst Rev; 2018 Jun; 6(6):CD012721. PubMed ID: 29952095
[TBL] [Abstract][Full Text] [Related]
9. Effect of Heart Failure Pharmacotherapies in Patients with Heart Failure with Mildly Reduced Ejection Fraction.
Schupp T; Bertsch T; Reinhardt M; Abel N; Schmitt A; Lau F; Abumayyaleh M; Akin M; Weiß C; Weidner K; Behnes M; Akin I
Eur J Prev Cardiol; 2024 Mar; ():. PubMed ID: 38513366
[TBL] [Abstract][Full Text] [Related]
10. Combination pharmacotherapies for cardiac reverse remodeling in heart failure patients with reduced ejection fraction: A systematic review and network meta-analysis of randomized clinical trials.
Bao J; Kan R; Chen J; Xuan H; Wang C; Li D; Xu T
Pharmacol Res; 2021 Jul; 169():105573. PubMed ID: 33766629
[TBL] [Abstract][Full Text] [Related]
11. Sex differences in efficacy of pharmacological therapies in heart failure with reduced ejection fraction: a meta-analysis.
Danielson C; Lileikyte G; Ouwerkerk W; S P Lam C; Erlinge D; Teng TK
ESC Heart Fail; 2022 Aug; 9(4):2753-2761. PubMed ID: 35603531
[TBL] [Abstract][Full Text] [Related]
12. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials.
Vaduganathan M; Claggett BL; Jhund PS; Cunningham JW; Pedro Ferreira J; Zannad F; Packer M; Fonarow GC; McMurray JJV; Solomon SD
Lancet; 2020 Jul; 396(10244):121-128. PubMed ID: 32446323
[TBL] [Abstract][Full Text] [Related]
13. Comparative Efficacy of Medical Treatments for Chronic Heart Failure: A Network Meta-Analysis.
Xiang B; Yu Z; Zhou X
Front Cardiovasc Med; 2021; 8():787810. PubMed ID: 35097007
[No Abstract] [Full Text] [Related]
14. Efficacy of new medical therapies in patients with heart failure, reduced ejection fraction, and chronic kidney disease already receiving neurohormonal inhibitors: a network meta-analysis.
Ameri P; De Marzo V; Zoccai GB; Tricarico L; Correale M; Brunetti ND; Canepa M; De Ferrari GM; Castagno D; Porto I
Eur Heart J Cardiovasc Pharmacother; 2022 Dec; 8(8):768-776. PubMed ID: 34928347
[TBL] [Abstract][Full Text] [Related]
15. SGLT2i versus ARNI in heart failure with reduced ejection fraction: a systematic review and meta-analysis.
Yan Y; Liu B; Du J; Wang J; Jing X; Liu Y; Deng S; Du J; She Q
ESC Heart Fail; 2021 Jun; 8(3):2210-2219. PubMed ID: 33749159
[TBL] [Abstract][Full Text] [Related]
16. Guideline-directed medical therapy in severe heart failure with reduced ejection fraction: An analysis from the HELP-HF registry.
Tomasoni D; Pagnesi M; Colombo G; Chiarito M; Stolfo D; Baldetti L; Lombardi CM; Adamo M; Maggi G; Inciardi RM; Loiacono F; Maccallini M; Villaschi A; Gasparini G; Montella M; Contessi S; Cocianni D; Perotto M; Barone G; Merlo M; Cappelletti AM; Rosano G; Sinagra G; Pini D; Savarese G; Metra M
Eur J Heart Fail; 2024 Feb; 26(2):327-337. PubMed ID: 37933210
[TBL] [Abstract][Full Text] [Related]
17. Prevention of sudden death in heart failure with reduced ejection fraction: do we still need an implantable cardioverter-defibrillator for primary prevention?
Abdelhamid M; Rosano G; Metra M; Adamopoulos S; Böhm M; Chioncel O; Filippatos G; Jankowska EA; Lopatin Y; Lund L; Milicic D; Moura B; Ben Gal T; Ristic A; Rakisheva A; Savarese G; Mullens W; Piepoli M; Bayes-Genis A; Thum T; Anker SD; Seferovic P; Coats AJS
Eur J Heart Fail; 2022 Sep; 24(9):1460-1466. PubMed ID: 35753058
[TBL] [Abstract][Full Text] [Related]
18. Thirty Years of Evidence on the Efficacy of Drug Treatments for Chronic Heart Failure With Reduced Ejection Fraction: A Network Meta-Analysis.
Burnett H; Earley A; Voors AA; Senni M; McMurray JJ; Deschaseaux C; Cope S
Circ Heart Fail; 2017 Jan; 10(1):e003529. PubMed ID: 28087688
[TBL] [Abstract][Full Text] [Related]
19. Safety and Efficacy of Traditional Heart Failure Therapies in Patients With Cardiac Amyloidosis and Heart Failure.
Yan CL; Gallo RA; Vasquez Martinez M; Rivera Rodriguez B; Trujillo L; Thakkar Rivera N; Hoffman JE
Am J Cardiol; 2023 Oct; 204():360-365. PubMed ID: 37573615
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF.
Jering KS; Zannad F; Claggett B; Mc Causland FR; Ferreira JP; Desai A; Barkoudah E; McMurray JJV; Pfeffer MA; Solomon SD
JACC Heart Fail; 2021 Jan; 9(1):13-24. PubMed ID: 33189633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
